Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
Spectacular as well :-)
CF "HVIVO will have a spectatular year"
That 6m trade appears to have been done @ 16.26 yesterday, when there had previously been buys going thro' well above 0.9.
Todays' RNS shows that George Stavrinidis now owns 19,547,295 shares.
He previously owned 25,547,295 shares.
He's sold 6m and the thresshold was crossed yesterday.
A bit of a coincidence? That trade may well have been his 6m shares.
Ahmedabad: ‘Sewage water tests can signal Covid-19'
Apr 19, 2020
extract
David Nilsson, director of the KTH Water Center says that significantly shorter detection time of virus in the wastewater will help us to get an early warning for a second virus wave. “International studies show that the virus can be tracked for weeks once defecated in the environment through excretion and hence we are hopeful to be successful in mapping the new coronavirus using wastewater,” he said.
hTTps://timesofindia.indiatimes.com/city/ahmedabad/sewage-water-tests-can-signal-covid/articleshow/75227358.cms
On BBC website , Coronavirus newsline this morning :
6:14
Something in the water
Australian officials want to start testing sewage for the virus
In Australia, the government has praised a research pilot where scientists have been able to find traces of the virus in raw sewage.
Health Minister Greg Hunt said the development meant authorities could soon track cases by monitoring wastewater levels.
Already in cities like Sydney, police regularly test the wastewater around suburbs to monitor drug use.
That same system could be used here and the CSIRO – Australia’s science agency – said it could be a shortcut to figuring out how many cases are in an area.
Their research comes off the back of similar analysis in the Netherlands and the US. Note that the scientists say drinking water - which is processed in plants - is “very well protected” against Sars-CoV-2 and other viruses.
Well , contrary to that opinion, only last night ORPH's CEO Cathal Friel in a podcast said that Chinese companies were very interested in a Corona virus Challenge Study that ORPH intend to run , and he is more than interested in dealing with them.
So obviously there are different opinions as could be seen with the UK G5 / Huawei agreement and ensuing debate.
Presumably the final lot from the seller .
SP now been able to rise as buys come in.
I'm afraid there will be no new material news that hasn't already been been reported to the market.
Yes, obviously any new news would have to be released to the market first before it could be added to a presentation available on its website.
Mistype , 2 x 15,318,073 = 30,636,146 . :-)
Lemming99,
I think we can be sure that LINK are now totally out.
The RNS today said that as at 7/4/20 , Link had 30,636,146 shares remaining.
Yesterday 8/4 , ther were 2 trades of 15,318,073 shares @ 1p at the times of 11.54 and 12.30.
2 x 15,318,073 = 15,318,073.
A coincidence? :-)
Expect an RNS early next week to confirm.
NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)
Details in NFX RNS of 3/12/18
==============================================================
Just recented announced
Genentech’s Esbriet gets FDA breakthrough status in uILD
4 March 2020
Roche Group unit Genentech has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for Esbriet (pirfenidone) to treat unclassifiable interstitial lung disease (uILD) in adults.
Esbriet holds approval to treat idiopathic pulmonary fibrosis (IPF) in more than 60 countries.
ILD is a group of more than 200 types of rare pulmonary diseases. Nearly 10% of patients reviewed by a multidisciplinary team cannot receive a definitive diagnosis, categorised as uILD.
The FDA granted the breakthrough designation comes from results of Phase II clinical trial, which assessed the safety and efficacy of Esbriet in uILD.
continues..
https://www.pharmaceutical-technology.com/news/genentech-esbriet-fda-breakthrough/
Can't buy at the moment with Halifax.
Won't get another further RNS from Lombard regarding holdings , unless they go back over 3%.
Nothing sinister - presumably because the price paid was below mid-price.
Any trade below mid-price shows as a sell.
Any trade above mid-price shows as a buy.
IMO the underlying value of ORPH is irrelevant as long as there are shareholders with large holding prepared to sell at around current prices.
As soon as holders stop selling at these prices ( or have sold all their shares ) and buyers are still interested then price will rise and value should see out.
Sounds obvious but a little more patience is needed.
20,000 willing... , not 20,000 selected!